Bob’s journey in the pharmaceutical industry began more than 35 years ago as a post-doctoral fellow in central nervous system (CNS) research at Schering-Plough Corporation. His natural affinity for helping those with mental illness is complemented by his drive to positively impact patients’ lives through innovation and bringing new drugs to market.
As Executive Vice President and Chief Strategy Officer and Interim Chief Medical Officer at Otsuka Pharmaceutical Development & Commercialization, Inc., Bob is responsible for coordinating the development strategy for Otsuka's compounds across their life cycles. He leads with a passion for clinical research and deep expertise in the discovery, development, and marketing of drugs for the treatment of mental illness and kidney diseases. In addition, Bob serves as President of the McQuade Center for Strategic Research and Development, LLC (a member of the global Otsuka family of pharmaceutical companies), which was formed to champion innovative early-stage research and development programs that have the potential to build the future portfolio of Otsuka products.
Prior to joining Otsuka in 2004, Bob held leadership positions within the Global Medical Affairs department at Bristol-Myers Squibb (BMS), where he was responsible for various products, including psychiatric treatments for generalized anxiety disorder and major depressive disorder. Most notably, Bob was an instrumental member of the team that helped form the strategic alliance between BMS and Otsuka to spearhead the development and commercialization of ABILIFY® (aripiprazole) in a number of indications. More recently, Bob played a significant role in the development and regulatory approval of Rexulti (brexpiprazole) and Jynarque (tolvaptan).
Bob received a Bachelor of Science from Davidson College and a Ph.D. from the University of North Carolina, Chapel Hill.
My personal goal throughout my career has been to bring important new drugs and innovations to patients, especially for those with serious mental illness, with the aim to make a meaningful difference in the lives of these patients.